New Zealand markets open in 9 hours 44 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
233.85+4.46 (+1.94%)
At close: 04:00PM EDT
228.55 -5.30 (-2.27%)
Pre-market: 07:00AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 28.07B
Enterprise value 26.95B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)31.75
Price/book (mrq)159.44
Enterprise value/revenue 30.48
Enterprise value/EBITDA -36.82

Trading information

Stock price history

Beta (5Y monthly) 0.74
52-week change 318.84%
S&P500 52-week change 3-4.45%
52-week high 3236.80
52-week low 3117.58
50-day moving average 3154.97
200-day moving average 3157.47

Share statistics

Avg vol (3-month) 3990.47k
Avg vol (10-day) 31.98M
Shares outstanding 5120.03M
Implied shares outstanding 6N/A
Float 8238.52M
% held by insiders 10.54%
% held by institutions 195.74%
Shares short (28 Jul 2022) 44.93M
Short ratio (28 Jul 2022) 47.9
Short % of float (28 Jul 2022) 44.84%
Short % of shares outstanding (28 Jul 2022) 44.11%
Shares short (prior month 29 Jun 2022) 44.79M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -110.91%
Operating margin (ttm)-80.82%

Management effectiveness

Return on assets (ttm)-13.06%
Return on equity (ttm)-190.54%

Income statement

Revenue (ttm)884.24M
Revenue per share (ttm)7.36
Quarterly revenue growth (yoy)1.90%
Gross profit (ttm)704.14M
EBITDA -671.94M
Net income avi to common (ttm)-980.72M
Diluted EPS (ttm)-7.49
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.11B
Total cash per share (mrq)8.79
Total debt (mrq)990.97M
Total debt/equity (mrq)562.93
Current ratio (mrq)3.76
Book value per share (mrq)1.46

Cash flow statement

Operating cash flow (ttm)-578.19M
Levered free cash flow (ttm)157.81M